IOLCPIOL Chemicals and Pharmaceuticals Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
IOL Chemicals and Pharmaceuticals Limited manufactures and sells pharmaceutical and chemical products in India and internationally. The company operates through, Chemical and Pharmaceutical segments. The Chemical segment offers ethyl acetate, iso butyl benzene, acetyl chloride, mono chloro acetic acid, and acetic anhydride to food processing, flexible packaging, pharmaceuticals, textiles, ink, paint, pesticides, and chemical intermediates industries. The Pharmaceutical segment provides active pharmaceutical ingredients, such as ibuprofen, metformin, fenofibrate, lamotrigine, clopidogrel bisulphate, pantoprazole sodium, ursodeoxycholic acid, losartan potassium, gabapentin, levetiracetam, and paracetamol. Its active pharmaceutical ingredients are used for the treatment of anti-inflammatory, analgesic and antipyretic, anti-diabetic, anti- platelet, anti-cholesterol, anti- convulsant, anti-epileptic, anti-hypertensive, and anti-cholelithic, as well as proton pump inhibitor. IOL Chemicals and Pharmaceuticals Limited was incorporated in 1986 and is based in Ludhiana, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on IOLCP — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why buy
- • Revenue growth: 17.4% YoY
- • Profit growth: 69.7% YoY
- • Debt/Equity: 0.08
- • RSI: 57
- • MACD: bullish
- • Price vs EMA21: above
Bull case
- • Revenue growth: 17.4% YoY
- • Profit growth: 69.7% YoY
- • Debt/Equity: 0.08
- • RSI: 57
Bear case
- • ROE: 7.9%
- • ROCE: 9.8%
- • Volume: 1.0x 20-day average
- • Volume trend: 0.9x baseline
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • ROE: 7.9%
- • ROCE: 9.8%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹10.73). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.